Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

被引：54

作者：

Ramalingam, S. ^{[1
]}

Yang, J. C. -H. ^{[2
]}

Lee, C. K. ^{[3
]}

Kurata, T. ^{[4
]}

Kim, D. -W. ^{[5
]}

John, T. ^{[6
]}

Nogami, N. ^{[7
]}

Ohe, Y. ^{[8
]}

Janne, P. A. ^{[9
]}

机构：

[1] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[3] St George Hosp, Med Oncol, Kogarah, NSW, Australia

[4] Kansai Med Univ, Dept Thorac Oncol, Hirakata Hosp, Osaka, Japan

[5] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[6] Austin Hlth Olivia Newton John Canc Res Inst, Med Oncol, Heidelberg, Vic, Australia

[7] Natl Hosp Org Shikoku Canc Ctr, Thorac Oncol, Matsuyama, Ehime, Japan

[8] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[9] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1016/S1556-0864(16)30324-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA1_PR

引用

页码：S152 / S152

页数：1